Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CEO Ian Mortimer sold 16,315 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $40.50, for a total transaction of $660,757.50. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,267,731. This represents a 34.26 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Ian Mortimer also recently made the following trade(s):
- On Friday, January 24th, Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $40.20, for a total value of $903,213.60.
Xenon Pharmaceuticals Trading Up 0.4 %
NASDAQ XENE traded up $0.16 during trading on Monday, reaching $40.11. 290,667 shares of the company's stock were exchanged, compared to its average volume of 383,885. Xenon Pharmaceuticals Inc. has a fifty-two week low of $35.53 and a fifty-two week high of $50.99. The company's fifty day simple moving average is $40.20 and its 200-day simple moving average is $40.82. The firm has a market capitalization of $3.06 billion, a PE ratio of -14.22 and a beta of 1.20.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.82) by $0.01. During the same quarter in the previous year, the business earned ($0.73) earnings per share. Equities analysts forecast that Xenon Pharmaceuticals Inc. will post -3.13 EPS for the current fiscal year.
Institutional Investors Weigh In On Xenon Pharmaceuticals
A number of institutional investors have recently modified their holdings of the stock. Blue Trust Inc. grew its holdings in shares of Xenon Pharmaceuticals by 174.7% during the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 641 shares in the last quarter. Avior Wealth Management LLC acquired a new stake in Xenon Pharmaceuticals during the fourth quarter valued at $101,000. nVerses Capital LLC purchased a new position in Xenon Pharmaceuticals in the third quarter valued at about $102,000. Mirae Asset Global Investments Co. Ltd. increased its position in Xenon Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock worth $106,000 after purchasing an additional 487 shares during the last quarter. Finally, KBC Group NV increased its position in Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 780 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Needham & Company LLC reiterated a "buy" rating and issued a $60.00 target price on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Finally, Raymond James reissued an "outperform" rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $56.00.
View Our Latest Stock Report on Xenon Pharmaceuticals
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
